Dr. Emmanuel S. Antonarakis

Dr. Emmanuel S. Antonarakis, MD, is a leading figure in genitourinary oncology and serves as the Clark Endowed Professor of Medicine at the University of Minnesota Medical School and Masonic Cancer Center. He also holds the role of Associate Director for Translational Research. A graduate of Columbia University College of Physicians and Surgeons, Dr. Antonarakis completed his residency in internal medicine at the University of California, San Francisco, followed by a hematology-oncology fellowship at Johns Hopkins University. Board-certified in medical oncology, he provides expert care for patients with advanced and metastatic prostate cancer, employing both in-person and virtual consultations.

Internationally recognized for his contributions to prostate cancer research, Dr. Antonarakis focuses on the development of novel biomarkers and precision therapies. He was instrumental in identifying the AR-V7 splice variant as a predictive biomarker for treatment resistance in metastatic prostate cancer, a discovery that has significantly influenced therapeutic decision-making. His research spans clinical trials, translational science, and molecular diagnostics aimed at personalizing treatment for men with hormone-sensitive and castration-resistant prostate cancer. With over 250 peer-reviewed publications, he is frequently invited to lecture at global conferences and serves on editorial boards for leading oncology journals.

Dr. Antonarakis is also a respected academic mentor and institutional leader. He has guided numerous fellows and junior faculty in the conduct of translational and clinical research and plays a key role in shaping the cancer center’s scientific strategy. His efforts have been recognized with awards for excellence in research and mentorship, and he remains actively involved in cooperative oncology groups and national research panels. Through his innovative research, compassionate care, and commitment to education, Dr. Antonarakis continues to shape the future of prostate cancer treatment and precision oncology.